Protalix BioTherapeutics (PLX) Revenue (2010 - 2026)

Protalix BioTherapeutics' Revenue history runs 17 years deep, the most recent figure standing at $33.8 million for Q1 2026.

• In Q1 2026, Revenue rose 233.73% year-over-year to $33.8 million; the TTM figure through Mar 2026 stood at $76.4 million (up 27.8% YoY), while the FY2025 annual figure was $52.7 million, down 1.23% from the prior year.
• Revenue was $33.8 million for Q1 2026 at Protalix BioTherapeutics, up from $9.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $35.1 million in Q2 2023 to a low of $3.7 million in Q1 2024.
• Historically, Revenue has averaged $14.9 million across 5 years, with a median of $13.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Revenue surged 300.72% in 2023, then plunged 61.59% in 2024.
• A 5-year view of Revenue shows it stood at $8.6 million in 2022, then gained by 21.69% to $10.5 million in 2023, then jumped by 73.74% to $18.2 million in 2024, then sank by 49.93% to $9.1 million in 2025, then soared by 269.98% to $33.8 million in 2026.
• The last three Revenue figures came in at $33.8 million (Q1 2026), $9.1 million (Q4 2025), and $17.9 million (Q3 2025), per Business Quant data.